This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea’s early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

Sign In or Create an Account

or View more offersArticle content

Highlights

Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content

  • Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials
  • Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas
  • Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea’s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies
  • Strengthens Fortrea’s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation
  • Supports Fortrea’s growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders
  • Supports Worldwide Clinical Trials’ existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease
  • Provides continuity of operations, study delivery and customer support throughout the transition through a strategic alliance agreement between the companies

Article content

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) and Worldwide Clinical Trials (“Worldwide”), leading global contract research organizations (CROs), today announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide’s Early Phase Services division (“Early Phase”), consisting of its Clinical Pharmacology Unit (CPU) and Bioanalytical Laboratory operations. The acquisition further enhances Fortrea’s position as a leading global clinical development partner, strengthening the front end of its development platform supporting customers across Phases I-IV. Worldwide will continue to support existing and future Phase I studies through its broader clinical development capabilities.

Article contentArticle content

The Early Phase business provides integrated early-phase clinical development and bioanalytical services supporting drug candidates from early development through later-stage clinical research. The business includes a Good Laboratory Practice (GLP)-compliant bioanalytical laboratory in Austin, Texas; a 200-bed Good Clinical Practice (GCP)-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas—enabling coordinated execution of complex early-phase studies with operational delivery services and reducing operational handoffs between clinical and bioanalytical functions, providing customers with a more streamlined path from first-in-human through proof-of-concept studies.

Article content

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

The acquisition complements Fortrea’s Clinical Pharmacology Services business and existing early phase capabilities by adding in-house large and small molecule bioanalytical capabilities and expanding its North American clinical research unit footprint. The addition of dedicated bioanalytical capabilities will enable Fortrea to improve turnaround times and deliver both simple and complex, integrated clinical development solutions. The combined platform will offer customers greater flexibility for complex and larger participant studies, broader access to distinct volunteer populations and expanded bedspace capacity across Fortrea’s early development network.

Article content

The agreement enables Worldwide to continue to provide core healthy volunteer study capabilities globally through its external site network, ensuring sponsors have access to the expertise and services needed across all phases of development, while accelerating investment within its rapidly growing late-stage business across therapeutic expertise, technology, geographic expansion and long-term growth initiatives.